Bimatoprost
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Bimatoprost
- Bimatoprost: From Glaucoma to Malformation Syndrome with Odontal and/or Periodontal Component
Bimatoprost: From Glaucoma to Malformation Syndrome with Odontal and/or Periodontal Component
One-Sentence Summary
Bimatoprost is a prostamide (prostaglandin F2-alpha analogue) eye drop, registered in South Africa as ophthalmic drops. The TxGNN model predicts it may be effective for malformation syndrome with odontal and/or periodontal component, with a very high score (99.997%). However, there are 0 clinical trials and 0 publications that mention bimatoprost for this condition, so the prediction is unsupported.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Glaucoma / ocular hypertension (general pharmacology; the SAHPRA indication text is not in the data provided) |
| Predicted New Indication | Malformation syndrome with odontal and/or periodontal component |
| TxGNN Prediction Score | 99.997% |
| Evidence Level | L5 (model prediction only) |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the Evidence Pack. From general pharmacology, bimatoprost is a prostamide/prostaglandin F2-alpha analogue that lowers intraocular pressure. Its known effects on the hair cycle (prolonging anagen, stimulating follicles) are the basis of its eyelash use.
We could not identify a plausible link between this pharmacology and a malformation syndrome involving the teeth or periodontium. The 20 papers retrieved for this prediction are general periodontitis literature: guidelines, reviews, and diabetes-periodontitis links. None mentions bimatoprost. The high TxGNN score is a network-proximity output, not evidence of benefit. It should be treated as a likely artefact.
Clinical Trial Evidence
Currently no related clinical trials registered. No SANCTR or PACTR entries were provided.
Literature Evidence
None of these papers studies bimatoprost. They are general periodontal literature, retrieved by the disease term only, and their relevance is still marked “pending”.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 35688447 | 2022 | Guideline | J Clin Periodontol | EFP clinical practice guideline for treating stage IV periodontitis |
| 35420698 | 2022 | Systematic review | Cochrane Database Syst Rev | Treating periodontitis for glycaemic control in people with diabetes |
| 29291254 | 2018 | Systematic review | Cochrane Database Syst Rev | Supportive periodontal therapy for maintaining dentition after periodontitis treatment |
| 22057194 | 2012 | Review | Diabetologia | Two-way relationship between periodontitis and diabetes |
| 37435999 | 2023 | Review | Periodontol 2000 | Complications and treatment errors in regenerative periodontal surgery |
| 39233377 | 2024 | Review | Periodontol 2000 | Sleep disorders as an emerging risk factor for periodontal health |
| 36883660 | 2023 | Review | J Dent Res | Role of gingival fibroblasts in periodontitis pathogenesis |
| 12010523 | 2002 | Review | J Clin Periodontol | Evidence-based view of scaling and root planing |
| 29193334 | 2018 | Review | Periodontol 2000 | Peri-implant vs periodontal soft tissues in health and disease |
| 9495612 | 1998 | Observational microbiology study | J Clin Periodontol | Microbial complexes in subgingival plaque |
South Africa Market Information
| Registration Number | Product Name | Dosage Form |
|---|---|---|
| Reg. No. 56/15.4/0781 | Glauptico | Drops |
| Reg. No. 54/15.4/0389.388 | Timpromat | Drops |
The approved indication text and Essential Medicines List status were not available in the data provided.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: This prediction is L5 (model score only), with no trials, no bimatoprost-specific literature, and no mechanistic link. Bimatoprost is a hair-growth-promoting eye drop, and nothing in the data connects it to a periodontal malformation syndrome.
Better-supported prediction in the same pack: The pack ranks alopecia 8th (score 99.993%, evidence level L2). It has 11 registered trials, including completed Phase 2 studies in androgenetic alopecia:
- NCT01904721: men, n=244
- NCT01325337: men, n=307
- NCT01325350: women, n=306
- NCT02170662: androgen-dependent scalp follicles, n=33
Efficacy outcomes are not in the pack, and no Phase 3 evidence is listed. I recommend re-running this report with alopecia as the primary indication. The two South African registrations are ophthalmic drops, so any scalp use would be off-label and would need a suitable formulation.
To proceed, the following is needed:
- SAHPRA package insert (warnings, contraindications, approved indication text)
- Mechanism of action data from DrugBank
- Outcome data from the alopecia Phase 2 trials
- For the periodontal prediction, any biological rationale at all, before further evaluation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.